Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

Analysis of global RNA synthesis at the single cell level following hypoxia.

Biddlestone J, Druker J, Shmakova A, Ferguson G, Swedlow JR, Rocha S.

J Vis Exp. 2014 May 13;(87). doi: 10.3791/51420.

PMID:
24895009
[PubMed - in process]
2.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

PMID:
24659719
[PubMed - in process]
Free PMC Article
3.

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine.

Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B.

Genome Med. 2013 Nov 29;5(11):103. doi: 10.1186/gm509. eCollection 2013.

PMID:
24286512
[PubMed]
Free PMC Article
4.

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE.

Leukemia. 2013 Oct;27(10):2094-6. doi: 10.1038/leu.2013.228. Epub 2013 Jul 31. No abstract available.

PMID:
23900138
[PubMed - indexed for MEDLINE]
5.

The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM.

J Pharmacol Exp Ther. 2013 Feb;344(2):378-87. doi: 10.1124/jpet.112.200832. Epub 2012 Dec 7.

PMID:
23220742
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW.

Cancer Cell. 2012 Nov 13;22(5):656-67. doi: 10.1016/j.ccr.2012.08.027.

PMID:
23153538
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia.

Ryba T, Battaglia D, Chang BH, Shirley JW, Buckley Q, Pope BD, Devidas M, Druker BJ, Gilbert DM.

Genome Res. 2012 Oct;22(10):1833-44. doi: 10.1101/gr.138511.112. Epub 2012 May 24.

PMID:
22628462
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R.

Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004.

PMID:
22169110
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH.

Pediatr Blood Cancer. 2012 Sep;59(3):576-9. doi: 10.1002/pbc.23383. Epub 2011 Oct 28.

PMID:
22038978
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial.

Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S, Hébert JR.

Breast Cancer Res Treat. 2012 Jan;131(1):99-109. doi: 10.1007/s10549-011-1738-1. Epub 2011 Sep 8.

PMID:
21901389
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Beyond BRAF in melanoma.

Daud A, Bastian BC.

Curr Top Microbiol Immunol. 2012;355:99-117. doi: 10.1007/82_2011_163. Review.

PMID:
21826607
[PubMed - indexed for MEDLINE]
12.

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, Druker BJ, Schuff KG, Corless CL.

J Mol Diagn. 2011 Sep;13(5):504-13. doi: 10.1016/j.jmoldx.2011.04.003. Epub 2011 Jul 2. Erratum in: J Mol Diagn. 2012 Jul;14(4):418.

PMID:
21726664
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.

Claiborn K.

J Clin Invest. 2011 Apr;121(4):1227-8. No abstract available.

PMID:
21630503
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Survey of activated FLT3 signaling in leukemia.

Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD.

PLoS One. 2011 Apr 28;6(4):e19169. doi: 10.1371/journal.pone.0019169.

PMID:
21552520
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA.

Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19.

PMID:
20959606
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ.

Cancer Res. 2010 Sep 15;70(18):7325-35. doi: 10.1158/0008-5472.CAN-10-0607. Epub 2010 Aug 31.

PMID:
20807813
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Attacking cancer at its root.

Thompson CB.

Cell. 2009 Sep 18;138(6):1051-4. doi: 10.1016/j.cell.2009.09.002.

PMID:
19766556
[PubMed - indexed for MEDLINE]
Free Article
18.

[Molecular mechanisms of action of some immunosuppressive drugs].

Liberman AC, Druker J, Refojo D, Arzt E.

Medicina (B Aires). 2008;68(6):455-64. Spanish.

PMID:
19147430
[PubMed - indexed for MEDLINE]
19.

Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.

Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM.

PLoS One. 2008;3(10):e3593. doi: 10.1371/journal.pone.0003593. Epub 2008 Oct 31.

PMID:
18974832
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW.

Leukemia. 2008 Jul;22(7):1354-60. doi: 10.1038/leu.2008.126. Epub 2008 Jun 12.

PMID:
18548107
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk